Search

Displaying results 5611 - 5620 of 10000 in total
  1. Drug

    Pegmusirudin

    go.drugbank.com/drugs/DB19220
    Investigational

    Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).

  2. Drug

    Duvakitug

    go.drugbank.com/drugs/DB19444
    Investigational

    Duvakitug is under investigation in clinical trial NCT05668013 (A Study to Evaluate the Long-term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease).

  3. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. … [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation

  4. Drug

    PRTX-100

    go.drugbank.com/drugs/DB05947
    Investigational

    PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases … These binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system.

  5. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation). … Fulzerasib has a monoisotopic molecular weight of 630.22 Da.

  6. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated … Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation

  7. Drug

    Piclidenoson

    go.drugbank.com/drugs/DB05511
    Investigational

    Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. … It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.

  8. Drug

    Telratolimod

    go.drugbank.com/drugs/DB19590
    Investigational

    Telratolimod has a monoisotopic molecular weight of 593.47 Da. … Telratolimod is under investigation in clinical trial NCT06680479 (Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

  9. Drug

    Rezivertinib

    go.drugbank.com/drugs/DB21471
    Investigational

    Rezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is under investigation in clinical trial NCT06955325 (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations).

  10. Drug

    Opnurasib

    go.drugbank.com/drugs/DB21583
    Investigational

    Opnurasib has a monoisotopic molecular weight of 525.2 Da. … Opnurasib is under investigation in clinical trial NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer